Investors-Gan & Lee

Careers | Investors | Patients and HCPS | Contact us

Careers Investors Patients and HCPS Contact us

Search

# Popular search #

Diabetes Oncology Medical Devices

Investors

Investors Financial Reports IR Appointment

FY2024 Financial Performance Overview

Operating Income (CNY)

3.045Billion
Increase by 16.77% YOY
Net Profit Attributable Parent (CNY)

615 Million
Increase by 80.75% YOY
Sales Income in China (CNY)

2.518Billion
Increase by 15.38% YOY
International Sales Income (CNY)

392Million
Increase by 20.15% YOY
R&D Input Ratio (R&D Input/Operating Income)

21.20%
R&D Investment 646 Million CNY
Equity Incentive(Around 87 Employees Granted)

7.04 Million
Shares of Restricted Stock Total Shares before the Grant of the Company 1.1849%
Shareholder Returns in 2024（CNY）

1 per share Cash Dividend
Profit Distribution Proposal of the Company 2024（CNY incl.tax）

599 Million Cash Dividend

Copyright © 2021 Gan & Lee Pharmaceuticals. All Rights Reserved. 京ICP备10213074号-1 | 京公网安备 11011202003900号

Our websites

Gangan Technology

Subscribe

You are now leaving the Gan & Lee website.

The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.

Continue Back